Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study)

References

• WheltonPK, CareyRM, AronowWS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–1324. doi:10.1161/HYP.000000000000006629133354
   PubMed Web of Science ®Google Scholar
• WilliamsB, ManciaG, SpieringW, et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2018;36(12):2284–2309. doi:10.1097/HJH.000000000000196130379783
   PubMed Web of Science ®Google Scholar
• CarrAA, PrisantLM. Losartan: first of a new class of angiotensin antagonists for the management of hypertension. J Clin Pharmacol. 1996;36(1):3–12. doi:10.1002/j.1552-4604.1996.tb04146.x8932538
   PubMed Web of Science ®Google Scholar
• MesserliFH, WeberMA, BrunnerHR. Angiotensin II receptor inhibition. A new therapeutic principle. Arch Intern Med. 1996;156(17):1957–1965. doi:10.1001/archinte.1996.004401600690108823149
   PubMedGoogle Scholar
• AbrahamHM, WhiteCM, WhiteWB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015;38(1):33–54. doi:10.1007/s40264-014-0239-725416320
   PubMed Web of Science ®Google Scholar
• TsoiB, AkioyamenLE, BonnerA, et al. Comparative efficacy of angiotensin II antagonists in essential hypertension: systematic review and network meta-analysis of randomised controlled trials. Heart Lung Circ. 2018;27(6):666–682. doi:10.1016/j.hlc.2017.06.72128807582
   PubMed Web of Science ®Google Scholar
• DimouC, AntzaC, AkrivosE, et al. A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension. J Hum Hypertens. 2019;33(3):188–201. doi:10.1038/s41371-018-0138-y30518809
   PubMed Web of Science ®Google Scholar
• LeeSE, KimYJ, LeeHY, et al. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, Phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin Ther. 2012;34(3):552–568, 568.e1–568.e9. doi:10.1016/j.clinthera.2012.01.024
   Web of Science ®Google Scholar
• LeeH, KimKS, ChaeSC, JeongMH, KimDS, OhBH. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension. Clin Ther. 2013;35(9):1337–1349. doi:10.1016/j.clinthera.2013.06.02123932463
   PubMed Web of Science ®Google Scholar
• YounJC, IhmSH, BaeJH, et al. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, Phase III clinical study. Clin Ther. 2014;36(10):1412–1421. doi:10.1016/j.clinthera.2014.07.00425092393
   PubMed Web of Science ®Google Scholar
• LeeJH, YangDH, HwangJY, et al. A randomized, double-blind, candesartan-controlled, parallel group comparison clinical trial to evaluate the antihypertensive efficacy and safety of fimasartan in patients with mild to moderate essential hypertension. Clin Ther. 2016;38(6):1485–1497. doi:10.1016/j.clinthera.2016.04.00527161546
   PubMed Web of Science ®Google Scholar
• LeeHY, KimCH, SongJK, et al. 24-hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension. Korean J Intern Med. 2017;32(6):1025–1036. doi:10.3904/kjim.2016.09429032666
   PubMed Web of Science ®Google Scholar
• Cardona-MunozEG, Lopez-AlvaradoA, Conde-CarmonaI, et al. Safety and efficacy of fimasartan in Mexican patients with grade 1–2 essential hypertension. Arch Cardiol Mex. 2017;87(4):316–325. doi:10.1016/j.acmx.2017.01.00128209359
   PubMed Web of Science ®Google Scholar
• HednerT, OparilS, RasmussenK, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens. 1999;12(4):414–417. doi:10.1016/S0895-7061(99)00082-510232502
   PubMed Web of Science ®Google Scholar
• StumpeKO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther. 2004;26(Suppl A):A33–A37. doi:10.1016/S0149-2918(04)90144-015291378
   PubMed Web of Science ®Google Scholar
• ZannadF, FayR. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundam Clin Pharmacol. 2007;21(2):181–190. doi:10.1111/j.1472-8206.2007.00464.x17391291
   PubMed Web of Science ®Google Scholar
• SmithDH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9):1207–1225. doi:10.2165/00003495-200868090-0000318547132
   PubMed Web of Science ®Google Scholar
• KarioK. Perfect 24-h management of hypertension: clinical relevance and perspectives. J Hum Hypertens. 2017;31(4):231–243. doi:10.1038/jhh.2016.6527604658
   PubMed Web of Science ®Google Scholar
• HermidaRC, AyalaDE, MojonA, SmolenskyMH, PortaluppiF, FernandezJR. Sleep-time ambulatory blood pressure as a novel therapeutic target for cardiovascular risk reduction. J Hum Hypertens. 2014;28(10):567–574. doi:10.1038/jhh.2014.124500721
   PubMed Web of Science ®Google Scholar
• YiJE, ShinJ, IhmSH, et al. Not nondipping but nocturnal blood pressure predicts left ventricular hypertrophy in the essential hypertensive patients: the Korean ambulatory blood pressure multicenter observational study. J Hypertens. 2014;32(10):1999–2004. doi:10.1097/HJH.000000000000027225023153
   PubMed Web of Science ®Google Scholar
• KarioK. Systemic hemodynamic atherothrombotic syndrome and resonance hypothesis of blood pressure variability: triggering cardiovascular events. Korean Circ J. 2016;46(4):456–467. doi:10.4070/kcj.2016.46.4.45627482253
   PubMed Web of Science ®Google Scholar
• UshijimaK, NakashimaH, ShigaT, et al. Different chronotherapeutic effects of valsartan and olmesartan in non-dipper hypertensive patients during valsartan treatment at morning. J Pharmacol Sci. 2015;127(1):62–68. doi:10.1016/j.jphs.2014.09.00425704020
   PubMed Web of Science ®Google Scholar